Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 4/20 | 0.63 |
| ▸ | LMNA | P02545 | 3/20 | 0.63 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.63 |
| ▸ | TSHR | P16473 | 3/20 | 0.60 |
| ▸ | TP53 | P04637 | 2/20 | 0.60 |
| ▸ | CA1 | P00915 | 1/20 | 0.60 |
| ▸ | CA2 | P00918 | 1/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.44 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Guaiacol SCHEMBL6712813 | 0.90 | TP53 (0.69) | CYP1A2LMNAAGTR1TSHRTP53 | |
| Guaiacol SCHEMBL27508645 | 0.89 | CYP1A2 (0.61) | CYP1A2LMNAAGTR1TSHRTP53 | |
| Guaiacol SCHEMBL10429895 | 0.88 | TSHR (0.67) | CYP1A2LMNAAGTR1TSHRTP53 | |
| Guaiacol SCHEMBL4245702 | 0.85 | TSHR (0.58) | CYP1A2LMNAAGTR1TSHRTP53 | |
| Guaiacol SCHEMBL27509885 | 0.80 | CA1 (0.86) | CYP1A2LMNAAGTR1TSHRTP53 | |
| Orthocresol SCHEMBL28388336 | 0.79 | CYP1A2 (0.57) | CYP1A2LMNAAGTR1TSHRCA1 | |
| SCHEMBL6002023 | 0.79 | CYP1A2 (0.66) | CYP1A2LMNAAGTR1TSHRTP53 | |
| SCHEMBL6002020 | 0.79 | CYP1A2 (0.66) | CYP1A2LMNAAGTR1TSHRTP53 | |
| SCHEMBL5595885 | 0.79 | CYP1A2 (0.61) | CYP1A2LMNAAGTR1TSHRKDM4E | |
| SCHEMBL5878268 | 0.79 | CYP1A2 (0.61) | CYP1A2LMNAAGTR1TSHRKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 177 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115957194-A | Solvent system for content in cold soft capsule and cold soft capsule | 人福普克药业（武汉）有限公司 | 2023-04-14 | — | — | CN | claimed |
| CN-115778911-A | Dextromethorphan hydrobromide and guaiacol glyceryl ether compound tablet and preparation method thereof | 山西兰花药业股份有限公司 | 2023-03-14 | — | — | CN | claimed |
| CN-110934872-B | Levohydroxyeugenol capsule and preparation method thereof | 太阳升(亳州)生物医药科技有限公司 | 2023-01-10 | — | — | CN | claimed |
| CN-115043811-A | Preparation method of 4- [ (2-methoxyphenoxy) methyl ] -1, 3-dioxolane-2-one | 苏州敬业医药化工有限公司 | 2022-09-13 | — | — | CN | claimed |
| CN-114533664-A | Compound oral liquid preparation of dextromethorphan hydrobromide and guaiacol glyceryl ether | 江苏广承药业有限公司 | 2022-05-27 | — | — | CN | claimed |
| CN-112526019-B | Method for detecting contents of various components in ammonia Meiyusu oral solution by using HPLC (high performance liquid chromatography) method | 四川逢春制药有限公司 | 2021-09-28 | — | — | CN | claimed |
| CN-112972439-A | Yumei effervescent tablet and preparation method thereof | 南京亿华药业有限公司 | 2021-06-18 | — | — | CN | claimed |
| CN-112649548-A | Method for detecting content of various impurities in Yumeisu oral liquid preparation by using HPLC method | 北京博达绿洲医药科技研究有限公司 | 2021-04-13 | — | — | CN | claimed |
| CN-112526019-A | Method for detecting contents of various components in ammonia Meiyusu oral solution by using HPLC (high performance liquid chromatography) method | 四川逢春制药有限公司 | 2021-03-19 | — | — | CN | claimed |
| CN-112526017-A | Method for detecting contents of various impurities in amimetu-yusu compound preparation by using HPLC (high performance liquid chromatography) method | 四川逢春制药有限公司 | 2021-03-19 | — | — | CN | claimed |
| CN-107782809-B | Method for detecting six active ingredients in drug sample | 人福普克药业（武汉）有限公司 | 2020-08-04 | — | — | CN | claimed |
| CN-111135156-A | New yufen bromo compound and its preparation method | 北京柏雅联合药物研究所有限公司 | 2020-05-12 | — | — | CN | claimed |
| US-20160109445-A1 | IDENTIFICATION OF BITTER LIGANDS THAT SPECIFICALLY ACTIVATE HUMAN T2R RECEPTORS AND RELATED ASSAYS FOR IDENTIFYING HUMAN BITTER TASTE MODULATORS | FIRMENICH INCORPORATED | 2016-04-21 | — | — | US | claimed |
| US-20140302528-A1 | IDENTIFICATION OF BITTER LIGANDS THAT SPECIFICALLY ACTIVATE HUMAN T2R RECEPTORS AND RELATED ASSAYS FOR IDENTIFYING HUMAN BITTER TASTE MODULATORS | SENOMYX, INC. (US) | 2014-10-09 | — | — | US | claimed |
| US-20140045695-A1 | Continuous Fiber Layer Comprising an Active Substance on the Basis of Bio-polymers, the Use Thereof, and Method for the Production Thereof | BASF SE (DE) | 2014-02-13 | — | — | US | claimed |
| EP-2661266-A2 | CHEMOSENSORY RECEPTOR LIGAND-BASED THERAPIES | Elcelyx Therapeutics, Inc. (US) | 2013-11-13 | — | — | EP | claimed |
| WO-2012094636-A2 | CHEMOSENSORY RECEPTOR LIGAND-BASED THERAPIES | ELCELYX THERAPEUTICS, INC. (US) | 2012-07-12 | — | — | WO | claimed |
| US-20110136669-A1 | Continuous Fiber Layer Comprising an Active Substance on the Basis of Bio-Polymers, the use Thereof, and Method for the Production Thereof | BASF SE (DE) | 2011-06-09 | — | — | US | claimed |
| CN-1615826-A | Guaiamar dripping pill | LUZHOU MEDICINE SCIENCE AND TE (CN) | 2005-05-18 | — | — | CN | claimed |
| CN-1354740-A | Pharmaceutical compounds | NICOX SA (FR) | 2002-06-19 | — | — | CN | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140045695-A1 | Continuous Fiber Layer Comprising an Active Substance on the Basis of Bio-polymers, the Use Thereof, and Method for the Production Thereof | CUTA, FGB, CD68 | CYP1A2 208/4885LMNA 1407/4885AGTR1 4586/4885 |
| US-20110136669-A1 | Continuous Fiber Layer Comprising an Active Substance on the Basis of Bio-Polymers, the use Thereof, and Method for the Production Thereof | CUTA, FGB, CD68 | CYP1A2 190/4885LMNA 1352/4885AGTR1 4587/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.